Clinical Trials
30 trialsSTRATEGIC-1
GERCOR - Multidisciplinary Oncology Cooperative Group
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
SELENIUM
Seoul National University Hospital
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Samsung Medical Center
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
MITO16MANGO2b
National Cancer Institute, Naples
BEVERLY
National Cancer Institute, Naples
RE-GEND
Kyorin University
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
SPBPDC
Qianfoshan Hospital
VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
Fudan University
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer
The Netherlands Cancer Institute
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
BEVAMAINT
Centre Hospitalier Universitaire Dijon
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
Fudan University
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
FERMATA
Biocad
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
TRIBE2
Gruppo Oncologico del Nord-Ovest
HIPOVA-01
Hospices Civils de Lyon
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
Sinocelltech Ltd.
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
Luye Pharma Group Ltd.
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
NSABP Foundation Inc
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Ludwig-Maximilians - University of Munich
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
Genentech, Inc.
CAIRO3
Dutch Colorectal Cancer Group
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Ludwig-Maximilians - University of Munich
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
National Cancer Institute (NCI)
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
Mast Therapeutics, Inc.